Mario Otto, MD, PhD, was recently awarded a 3-year grant in the amount of $75,000 from Cannonball Kids’ Cancer Foundation for his clinical trial entitled, “TCR-α/β+ and CD19+ depleted KIR/KIR ligand-mismatched Haploidentical Hematopoietic Stem Cell Transplant and Zoledronate for Pediatric Relapsed/Refractory Hematologic Malignancies and High Risk Solid Tumors.” Funds from this award will be used in a clinical trial for children with relapsed or refractory hematologic malignancies and high-risk solid tumors (such as rhabdomyosarcoma, neuroblastoma, Ewing sarcoma), utilizing haploidentical hematopoietic stem cell (HSC) transplantation employing a novel, highly selective graft engineering process that removes unwanted cellular components (e.g., α/β T cells and B cells). The CEO, Ashley VanDerMark, and co-founder of Cannonball Kids’, Melissa Wiggins, recently visited with Dr. Otto at his laboratory in Madison.